Total and biologically active serum-soluble CD154 in patients with chronic idiopathic urticaria

Allergy and Asthma Proceedings

Volumn 25, Issue 2, 2004, Pages 121-125

  Garmendia, Jenny V ^a,b   Zabaleta, Mercedes ^a   Blanca, Isaac ^a   Bianco, Nicolás E ^a   De Sanctis, Juan B ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b Central University of Venezuela Miami Campus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; AUTOIMMUNITY; BIOASSAY; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MOLECULAR DYNAMICS; PATHOGENESIS; QUANTITATIVE ANALYSIS; SEX RATIO; SKIN TEST;

ADULT; AUTOANTIGENS; BIOLOGICAL ASSAY; CASE-CONTROL STUDIES; CD40 LIGAND; CHRONIC DISEASE; EOSINOPHILS; FEMALE; HUMANS; IMMUNOGLOBULIN E; INTRADERMAL TESTS; LEUKOCYTE COUNT; MALE; MAST CELLS; URTICARIA;

EID: 2442619250     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Greaves MW. Pathophysiology of chronic urticaria. Int Arch Allergy Immunol 127:3-9, 2002.
2. Sabroe RA, Francis DM, Barr RM, et al. Anti-FcεRI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 102:651-658, 1998.
3. Kikuchi Y, and Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 107:1056-1062, 2001.
4. Marone G, Spadaro G, Palumbo C, and Condorelli G. The anti-IgE/anti-FcεRIα autoantibody network in allergic autoimmune disease. Clin Exp Allergy 29:17-27, 1999.
5. Tong LJ, Balakrsinan G, Kochan JP, et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 99:461-465, 1997.
6. Kotzin BL. Mechanisms of autoimmunity. In Clinical Immunology Principles and Practice, 2nd ed. Rich RR, Fleisher TA, Shearer WT, Kotzin BL, and Schroeder HW Jr (Eds). Philadelphia: Mosby Publishers, 58.1-58.13, 2001.
7. van Kooten C, and Banchereau J. CD40-CD40 ligand. J Leukoc Biol 67:2-17, 2000.
8. Calderhead DM, Kosaka Y, Manning EM, and Noelle RJ. CD40-CD154 interactions in B-cell signaling. Curr Top Microbiol Immunol 245:73-99, 2000.
9. Vakkalanka RK, Woo C, Kirou KA, et al. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42:871-881, 1999.
10. Tamura N, Kobayashi S, Kato K, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 28:2583-2590, 2001.
11. 1. Mehling A, Loser K, Varga G, et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 194:615-628, 2001.
12. Daikh DI, and Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol 490:113-117, 2001.
13. Burkly LC. CD40 pathway blockade as an approach to immunotherapy. Adv Exp Med Biol 489:135-152, 2001.
14. Toubi E, Adir-Shani A, Kessel A, et al. Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 20:371-378, 2000.
15. Confino-Cohen R, Aharoni D, Goldberg A, et al. Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with idiopathic urticaria. J Allergy Clin Immunol 109:349-356, 2002.
16. Gulbins E, Brenner B, Schlottmann K, et al. Activation of the Ras signaling pathway by the CD40 receptor. J Immunol 157:2844-2850, 1996.
17. Benedetti MS, Plisnier M, Kaise J, et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 57:571-582, 2001.
18. Claveau J, Lavore A, Brunet C, et al. Chronic idiopathic urticaria: Possible contribution of histamine releasing factors to pathogenesis. J Allergy Clin Immunol 92:132-137, 1993.
19. Grattan CEH, Hamon CGB, Cowan MA, and Leeming RJ. Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria. Br J Dermatol 119:179-184, 1988.
20. Gruber BL, Baeza ML, Marchese MJ, et al. Presence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 90:213-217, 1988.
21. Imaizumi K, Kawabe T, Ichiyama S, et al. Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD140 ligand interaction. Am J Physiol 21:L49-L57, 1999.
22. Mazzei GJ, Edgerton MD, Losberger C, et al. Recombinant soluble CD40 ligand is biologically active. J Biol Chem 270:7025-7028, 1995.
23. Zabaleta M, Marino R, Borges J, et al. Activity profile in multiple sclerosis: An integrative approach. A preliminary report. Mult Scler 8:343-349, 2002.
24. Henz BM, Maurer M, Lippert U, et al. Mast cells as initiators of immunity and host defense. Exp Dermatol 10:1-10, 2001.
25. Pawankar R, Okuda M, Yssel H, et al. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilon RI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99:1492-1499, 1997.